Silent coronary artery disease in type 2 diabetes mellitus: The role of Lipoprotein(a), homocysteine and apo(a) polymorphism

Cardiovascular Diabetology

Volumn 1, Issue , 2002, Pages

  Gazzaruso, Carmine ^a   Garzaniti, Adriana ^b   Giordanetti, Stefano ^a   Falcone, Colomba ^c   Fratino, Pietro ^a  

^a IRCCS   (Italy)

^b Diabetes   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HOMOCYSTEINE; INSULIN; LIPOPROTEIN A; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANAMNESIS; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE DURATION; DNA POLYMORPHISM; DYSLIPIDEMIA; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; GROUPS BY AGE; GROUPS BY SEX; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; METABOLIC PARAMETERS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; PREDICTION; PROTEIN FUNCTION; SCINTIGRAPHY; SILENT MYOCARDIAL INFARCTION; SMOKING; SYMPTOMATOLOGY;

EID: 2442460716     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-1-5     Document Type: Article

References (37)

1. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease: a meta-analysis of prospective studies. Circulation 2000, 102:1082-1085
2. Gerhard GT, Duell PB: Homocysteine and atherosclerosis. Curr Opin Lipidol 1999, 10:417-428
3. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G: Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992, 89:1040-1046
4. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Mühlberger V, Schönitzer D, Utermann G: Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996, 16:713-719
5. Gazzaruso C, Buscaglia P, Garzaniti A, Falcone C, Mariotti S, Savino S, Bonetti G, Finardi F, Geroldi D: Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. J Hypertens 1997, 15:227-235
6. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H: The low molecular weight apo(a) phenotype is an independent risk factor for coronary artery disease in hemodialysis patients: a prospective followup. J Am Soc Nephrol 1999, 10:1027-1036
7. Gazzaruso C, Garzaniti A, Buscaglia P, Bonetti G, Falcone C, Fratino P, Finardi G, Geroldi D: Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol 1999, 33:157-163
8. Paultre F, Pearson TA, Weil HFC, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L: High levels of Lp(a) wth a small apo(a) isoform are associated with coronary artery disease in African American and White men. Arterioscl Thromb Vasc Biol 2000, 20:2619-2625
9. Koistinen MJ: Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. BMJ 1990, 301:92-95
10. Naka M, Hiramatsu K, Aizawa T, Momose A, Yoshozawa K, Shigematsu S, Ishihara F, Niwa A, Yamada T: Silent myocardial ischemia in patients with non-insulin dependent diabetes mellitus as adjusted by treadmill exercise testing and coronary angiography. Am Heart J 1992, 123:46-53
11. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group: Prevalence of unrecognized silent myocardial ischemia and its association with aterosclerotic risk factors in non-insulin dependent diabetes mellitus. Am J Cardiol 1997, 79:134-139
12. Cohn PF: Prognosis for patients with different types of silent CAD. Circulation 1987, 5:33-35
13. Weiner DA, Ryan TJ, Pearsons L, Fisher LD, Chaitman BR, Sheffield LT, Tristani FE: Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus: a report from the Coronary Artery Surgery Study (CASS) Registry. Am J Cardiol 1991, 68:729-734
14. American Diabetes Association: Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 1998, 21:1551-1559
15. Ruiz J, Thillet J, Huby T, James RW, Erlich D, Flandre P, Froguel P, Chapman J, Passa P: Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia 1994, 37:585-591
16. Haffner SM, Moss SE, Klein BEK, Klein R: Lack of association between Lipoprotein(a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin epidemiologic study of diabetic retinopathy. Metabolism 1992, 41:194-197
17. Gazzaruso C, Garzaniti A, Falcone C, Geroldi D, Finardi G, Fratino P: Association of Lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in type 2 diabetic patients and in non diabetic subjects. Diabet Med 2001, 18:589-594
18. Yeromenko Y, Lavie L, Levy Y: Homocysteine and cardiovascular risk in patients with diabetes mellitus. Nutr Metab Cardiovasc Dis 2001, 11:108-116
19. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jacobs C, Bouter LM, Heine RJ, Stehouwer CDA: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus. A population-based study. Arterioscler Thromb Vasc Biol 1998, 18:133-138
20. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJG, Stehouwer CDA, Silberbusch J: Fasting and post-methionine homocysteine levels in NIDDM. Diabetes Care 1999, 22:125-132
21. Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G, Kosada S, Takahashi S, Miyamori I: Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 1999, 22:484-490
22. Kark JD, Selhub J, Bostom A, Rosenberg IH: Plasma homocysteine and all-cause mortality in diabetes. Lancet 1999, 353:1936-1937
23. Gazzaruso C, Garzaniti A, Giordanetti S, Falcone C, De Amici E, Geroldi D, Fratino P: Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients. A role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care 2002, 25:1418-1424
24. The Expert Committee on the diagnosis and classification of diabetes mellitus: Report of the Expert Committee on the Diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197
25. . 1999 WHO-ISH: Guidelines for the management of hypertension. J Hypertens 1999, 17:151-183
26. Rose GA, Blackburn H: Cardiovascular survey methods. Monograph series WHO 1968, 56:
27. Falcone C, De Servi S, Poma E, Campana C, Scire A, Montemartini C, Specchia G: Clinical significance of exercise-induced silent myocardial ischaemia in patients with coronary artery disease. J Am Coll Cardiol 1987, 9:295-299
28. Ewing DJ, Clarke BF: Diagnosis and management of diabetic autonomic neuropathy. BMJ 1982, 285:916-918
29. Li KM, Wilckenn DEL, Dudman NPB: Effect of serum Lipoprotein(a) on estimation of low density lipoprotein cholesterol by the Friedewald formula. Clin Chem 1994, 40:571-573
30. Geroldi D, Bellotti V, Buscaglia P, Bonetti G, Gazzaruso C, Caprioli A, Fratino P: Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin Chim Acta 1993, 221:159-169
31. Gazzaruso C, Garzaniti A, Buscaglia P, Bonetti G, Falcone C, Fratino P, Finardi G, Geroldi D: Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. J Cardiovasc Risk 1998, 5:37-42
32. Boerwinkle E, Leffert CC, Lin C, Lackner G, Chiesa G, Hobbs HH: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentration. J Clin Invest 1992, 90:52-60
33. Koistinen MJ, Huikuri HV, Horhonen UR, Linnaluoto MK, Kuusi T, Takkunen JT, Taskinen MR: Asymptomatic coronary artery disease in diabetes: relation to common risk factor, lipoproteins, apoproteins and apoE polymorphism. Acta Diabetol 1994, 31:210-214
34. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V: Silent myocardial ischemia in patients with diabetes. Who to screen. Diabetes Care 1999, 22:1396-1400
35. Airaksinen KEJ, Koistinen MJ: Association between silent coronary artery disease, diabetic and autonomic neuropathy. Fact or fallacy? Diabetes Care 1992, 15:288-292
36. Earle KA, Mishra M, Morocutti A, Barnes D, Stephens E, Chambers J, Viberti GC: Microalbuminuria as a marker of silent myocardial ischemia in IDDM patients. Diabetologia 1996, 39:854-856
37. Rutter MK, McComb JM, Brady S, Marshall SM: Silent Myocardial Ischemia and microalbuminuria in asymptomatic subjects with non-insulin dependent diabetes mellitus. Am J Cardiol 1999, 83:27-31